BIOMAT Database Logo BIOMAT Database Logo

Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia. 2023

Atsunori Kaneshige, and Longchuan Bai, and Mi Wang, and Donna McEachern, and Jennifer L Meagher, and Renqi Xu, and Paul D Kirchhoff, and Bo Wen, and Duxin Sun, and Jeanne A Stuckey, and Shaomeng Wang
Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.

STAT5 is an attractive therapeutic target for human cancers. We report herein the discovery of a potent and selective STAT5 degrader with strong antitumor activity in vivo. We first obtained small-molecule ligands with sub-micromolar to low micromolar binding affinities to STAT5 and STAT6 SH2 domains and determined co-crystal structures of three such ligands in complex with STAT5A. We successfully transformed these ligands into potent and selective STAT5 degraders using the PROTAC technology with AK-2292 as the best compound. AK-2292 effectively induces degradation of STAT5A, STAT5B, and phosphorylated STAT5 proteins in a concentration- and time-dependent manner in acute myeloid leukemia (AML) cell lines and demonstrates excellent degradation selectivity for STAT5 over all other STAT members. It exerts potent and specific cell growth inhibitory activity in AML cell lines with high levels of phosphorylated STAT5. AK-2292 effectively reduces STAT5 protein in vivo and achieves strong antitumor activity in mice at well-tolerated dose schedules.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015470 Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Leukemia, Myelogenous, Acute,Leukemia, Nonlymphocytic, Acute,Myeloid Leukemia, Acute,Nonlymphocytic Leukemia, Acute,ANLL,Acute Myelogenous Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with Maturation,Acute Myeloid Leukemia without Maturation,Leukemia, Acute Myelogenous,Leukemia, Acute Myeloid,Leukemia, Myeloblastic, Acute,Leukemia, Myelocytic, Acute,Leukemia, Myeloid, Acute, M1,Leukemia, Myeloid, Acute, M2,Leukemia, Nonlymphoblastic, Acute,Myeloblastic Leukemia, Acute,Myelocytic Leukemia, Acute,Myelogenous Leukemia, Acute,Myeloid Leukemia, Acute, M1,Myeloid Leukemia, Acute, M2,Nonlymphoblastic Leukemia, Acute,Acute Myeloblastic Leukemia,Acute Myeloblastic Leukemias,Acute Myelocytic Leukemia,Acute Myelocytic Leukemias,Acute Myelogenous Leukemias,Acute Myeloid Leukemias,Acute Nonlymphoblastic Leukemia,Acute Nonlymphoblastic Leukemias,Acute Nonlymphocytic Leukemia,Acute Nonlymphocytic Leukemias,Leukemia, Acute Myeloblastic,Leukemia, Acute Myelocytic,Leukemia, Acute Nonlymphoblastic,Leukemia, Acute Nonlymphocytic,Leukemias, Acute Myeloblastic,Leukemias, Acute Myelocytic,Leukemias, Acute Myelogenous,Leukemias, Acute Myeloid,Leukemias, Acute Nonlymphoblastic,Leukemias, Acute Nonlymphocytic,Myeloblastic Leukemias, Acute,Myelocytic Leukemias, Acute,Myelogenous Leukemias, Acute,Myeloid Leukemias, Acute,Nonlymphoblastic Leukemias, Acute,Nonlymphocytic Leukemias, Acute
D050799 STAT5 Transcription Factor A signal transducer and activator of transcription that mediates cellular responses to a variety of CYTOKINES. Stat5 activation is associated with transcription of CELL CYCLE regulators such as CYCLIN KINASE INHIBITOR P21 and anti-apoptotic genes such as BCL-2 GENES. Stat5 is constitutively activated in many patients with acute MYELOID LEUKEMIA. Mammary Gland Factor,Mammary Gland-Specific Nuclear Factor,STAT5 Protein,STAT5a Protein,STAT5a Transcription Factor,STAT5alpha Protein,STAT5b Protein,STAT5b Transcription Factor,STAT5beta Protein,Signal Transducer and Activator of Transcription 5,Signal Transducer and Activator of Transcription 5A,Signal Transducer and Activator of Transcription 5B,Factor, STAT5 Transcription,Mammary Gland Specific Nuclear Factor,Transcription Factor, STAT5,Transcription Factor, STAT5a,Transcription Factor, STAT5b
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D018909 src Homology Domains Regions of AMINO ACID SEQUENCE similarity in the SRC-FAMILY TYROSINE KINASES that fold into specific functional tertiary structures. The SH1 domain is a CATALYTIC DOMAIN. SH2 and SH3 domains are protein interaction domains. SH2 usually binds PHOSPHOTYROSINE-containing proteins and SH3 interacts with CYTOSKELETAL PROTEINS. SH Domains,SH1 Domain,SH2 Domain,SH3 Domain,src Homology Region 2 Domain,Homology Domain, src,Homology Domains, src,SH Domain,SH1 Domains,SH2 Domains,SH3 Domains,src Homology Domain

Related Publications

Atsunori Kaneshige, and Longchuan Bai, and Mi Wang, and Donna McEachern, and Jennifer L Meagher, and Renqi Xu, and Paul D Kirchhoff, and Bo Wen, and Duxin Sun, and Jeanne A Stuckey, and Shaomeng Wang
Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong in vivo Antitumor Activity.
August 2023, Journal of medicinal chemistry,
Atsunori Kaneshige, and Longchuan Bai, and Mi Wang, and Donna McEachern, and Jennifer L Meagher, and Renqi Xu, and Paul D Kirchhoff, and Bo Wen, and Duxin Sun, and Jeanne A Stuckey, and Shaomeng Wang
Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia.
January 2024, European journal of medicinal chemistry,
Atsunori Kaneshige, and Longchuan Bai, and Mi Wang, and Donna McEachern, and Jennifer L Meagher, and Renqi Xu, and Paul D Kirchhoff, and Bo Wen, and Duxin Sun, and Jeanne A Stuckey, and Shaomeng Wang
Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity.
September 2023, Journal of medicinal chemistry,
Atsunori Kaneshige, and Longchuan Bai, and Mi Wang, and Donna McEachern, and Jennifer L Meagher, and Renqi Xu, and Paul D Kirchhoff, and Bo Wen, and Duxin Sun, and Jeanne A Stuckey, and Shaomeng Wang
Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader.
April 2024, Journal of medicinal chemistry,
Atsunori Kaneshige, and Longchuan Bai, and Mi Wang, and Donna McEachern, and Jennifer L Meagher, and Renqi Xu, and Paul D Kirchhoff, and Bo Wen, and Duxin Sun, and Jeanne A Stuckey, and Shaomeng Wang
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.
December 2019, Nature medicine,
Atsunori Kaneshige, and Longchuan Bai, and Mi Wang, and Donna McEachern, and Jennifer L Meagher, and Renqi Xu, and Paul D Kirchhoff, and Bo Wen, and Duxin Sun, and Jeanne A Stuckey, and Shaomeng Wang
Discovery of a potent Gilteritinib-based FLT3-PROTAC degrader for the treatment of Acute myeloid leukemia.
May 2024, Bioorganic chemistry,
Atsunori Kaneshige, and Longchuan Bai, and Mi Wang, and Donna McEachern, and Jennifer L Meagher, and Renqi Xu, and Paul D Kirchhoff, and Bo Wen, and Duxin Sun, and Jeanne A Stuckey, and Shaomeng Wang
Discovery of a potent and selective JAK1-targeting PROTAC degrader with anti-tumor activities.
June 2024, Bioorganic & medicinal chemistry letters,
Atsunori Kaneshige, and Longchuan Bai, and Mi Wang, and Donna McEachern, and Jennifer L Meagher, and Renqi Xu, and Paul D Kirchhoff, and Bo Wen, and Duxin Sun, and Jeanne A Stuckey, and Shaomeng Wang
Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13.
August 2022, Journal of medicinal chemistry,
Atsunori Kaneshige, and Longchuan Bai, and Mi Wang, and Donna McEachern, and Jennifer L Meagher, and Renqi Xu, and Paul D Kirchhoff, and Bo Wen, and Duxin Sun, and Jeanne A Stuckey, and Shaomeng Wang
A selective Fibroblast Growth Factor Receptor 1/2 PROTAC degrader with antitumor activity.
April 2024, Molecular cancer therapeutics,
Atsunori Kaneshige, and Longchuan Bai, and Mi Wang, and Donna McEachern, and Jennifer L Meagher, and Renqi Xu, and Paul D Kirchhoff, and Bo Wen, and Duxin Sun, and Jeanne A Stuckey, and Shaomeng Wang
Discovery of Selective and Potent ATR Degrader for Exploration its Kinase-Independent Functions in Acute Myeloid Leukemia Cells.
April 2024, Angewandte Chemie (International ed. in English),
Copied contents to your clipboard!